Johnson & Johnson acquires Abiomed for more than 16,700 million

Nov. 1 () –

Johnson & Johnson, a multinational dedicated to health care products, has acquired Abiomed, a world leader in cardiac, pulmonary and renal support technologies, for more than 16,600 million dollars (16,702 million euros), as reported by the company it’s a statement.

Specifically, this purchase consolidates Johnson & Johnson MedTech’s (JJMT) position in the cardiovascular care segment, with cardiovascular disease being the number one cause of death today.

Abiomed is a pioneer provider in the cardiovascular medical technology market, with a unique portfolio for the treatment of coronary artery disease and heart failure.

“The addition of Abiomed is an important step in executing our strategic priorities and our vision for the new Johnson & Johnson focused on the pharmaceutical and MedTech industry. The addition of Abiomed provides a strategic platform to promote innovative treatments in cardiovascular diseases and help to more patients around the world while creating value for our shareholders,” said Johnson & Johnson CEO Joaquín Duato.

For his part, the president and CEO of Abiomed, Michael R. Minogue, welcomed the purchase. “This transaction partners us with an organization that shares our mindset of putting patients first and creates immediate value for our patients, customers, employees and shareholders. It will allow us to leverage the company’s global scale, commercial strength and clinical expertise to accelerate our mission.” to make heart recovery the global standard of care,” he said.